Natixis Advisors
ACAD icon

Natixis Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Natixis Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.44M Buy
135,958
+35,559
+35% +$782K ﹤0.01% 1042
2026
Q1 		$2.23M Buy
100,399
+28,747
+40% +$687K ﹤0.01% 1080
2025
Q4 		$1.91M Buy
71,652
+7,418
+12% +$177K ﹤0.01% 1062
2025
Q3 		$1.37M Sell
64,234
-7,944
-11% -$188K ﹤0.01% 1218
2025
Q2 		$1.56M Buy
72,178
+9,283
+15% +$173K ﹤0.01% 1166
2025
Q1 		$1.04M Buy
62,895
+15,888
+34% +$289K ﹤0.01% 1262
2024
Q4 		$863K Buy
47,007
+6,519
+16% +$105K ﹤0.01% 1347
2024
Q3 		$623K Buy
40,488
+14,961
+59% +$250K ﹤0.01% 1414
2024
Q2 		$415K Buy
25,527
+7,697
+43% +$124K ﹤0.01% 1471
2024
Q1 		$330K Sell
17,830
-23,045
-56% -$571K ﹤0.01% 1464
2023
Q4 		$1.28M Buy
40,875
+6,112
+18% +$146K ﹤0.01% 1138
2023
Q3 		$724K Buy
34,763
+9,676
+39% +$263K ﹤0.01% 1257
2023
Q2 		$601K Buy
25,087
+11,110
+79% +$247K ﹤0.01% 1293
2023
Q1 		$263K Buy
+13,977
New +$266K ﹤0.01% 1425

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Natixis Advisors's ACAD Position: Q2 2026 in Review

Natixis Advisors increased its Acadia Pharmaceuticals (ACAD) stake by 35% in Q2 2026, buying an estimated $782K and bringing the position to 135,958 shares worth $3.44M. The position accounts for ﹤0.01% of the portfolio, ranked #1042.

Natixis Advisors first reported a position in ACAD in Q1 2023 and has held it in 14 quarters since. 353 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Natixis Advisors held 135,958 shares of Acadia Pharmaceuticals worth $3.44M as of Q2 2026.
  • Natixis Advisors bought 35,559 Acadia Pharmaceuticals shares in Q2 2026, an estimated $782K.
  • Acadia Pharmaceuticals made up ﹤0.01% of Natixis Advisors's portfolio in Q2 2026, its #1042 holding.
  • Natixis Advisors first reported a position in Acadia Pharmaceuticals in Q1 2023 and has held it in 14 quarters since.
  • 353 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Natixis Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.